vla15
Vaccineexperimental
Clinical trial activity
7 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
3
Phase 4
0
Earliest trial started Jan 1, 2017 (NCT03010228)
Timeline
Indications
Mechanism of action
- Fructose-1,6-bisphospate aldolaseImmunity, active
ald immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vla15
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07226882 | Phase 3 | Nov 17, 2025 | Pfizer |
| NCT05634811 | Phase 3 | Dec 12, 2022 | Pfizer |
| NCT05477524 | Phase 3 | Aug 4, 2022 | Pfizer, Valneva |
| NCT04801420 | Phase 2 | Mar 15, 2021 | Pfizer, Valneva |
| NCT03970733 | Phase 2 | Jul 31, 2019 | Valneva |
| NCT03769194 | Phase 2 | Dec 17, 2018 | Valneva |
| NCT03010228 | Phase 1 | Jan 1, 2017 | Valneva |
Showing 7 of 7 trials
Page 1 / 1